Collegium Pharmaceutical (COLL) Accumulated Expenses (2014 - 2026)

Collegium Pharmaceutical has reported Accumulated Expenses for 13 years, with the latest figure at $71.2 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 19.88% year-over-year to $71.2 million in Q2 2026; TTM through Jun 2026 was $71.2 million, a 19.88% increase from a year earlier, with the FY2025 full-year figure at $62.5 million, down 13.39% from the prior year.
• Accumulated Expenses was $71.2 million for Q2 2026 at Collegium Pharmaceutical, up from $58.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $72.1 million in Q4 2024, with the low at $22.8 million in Q3 2022.
• Average Accumulated Expenses over 5 years is $45.7 million, with a median of $40.4 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 143.09% in 2022, then slumped 40.51% in 2023.
• Over 5 years, Accumulated Expenses stood at $36.1 million in 2022, then climbed by 3.99% to $37.6 million in 2023, then jumped by 91.97% to $72.1 million in 2024, then dropped by 13.39% to $62.5 million in 2025, then increased by 14.07% to $71.2 million in 2026.
• The last three Accumulated Expenses figures came in at $71.2 million (Q2 2026), $58.1 million (Q1 2026), and $62.5 million (Q4 2025), per Business Quant data.